ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 884,26
0,08%
DAX
18 430,05
1,42%
Brent Oil
82,905
-0,68%
Bitcoin
63 085,35
-0,13%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MiNK Therapeutics Inc (INKT)

  7. MiNK Therapeutics Inc (INKT) Actualités

INKT MiNK Therapeutics Inc

0,9499
0,0092 (0,98%)
Après les heures de négociation
Dernière mise à jour : 22:41:46
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
MiNK Therapeutics Inc INKT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0092 0,98% 0,9499 22:41:46
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,9405 0,9235 0,9774 0,9301 0,9407
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202413:30GLOBEMiNK to Provide Corporate Update and First Quarter 2024..
08/4/202418:00GLOBEMiNK Therapeutics Announces Promising Preclinical Activity..
21/3/202412:26IHMARKETNEWSU.S. Index Futures Rise as Fed’s Dovish Outlook Spurs..
21/3/202412:00GLOBEMiNK Reports Fourth Quarter and Year-End 2023 Results
07/3/202413:30GLOBEMiNK to Provide Corporate Update and Fourth Quarter & Full..
06/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:05EDGAR2Form 8-K - Current report
14/2/202414:00EDGAR2Form 8-K - Current report
14/2/202414:00GLOBEFirst Refractory Gastric Cancer Patient Dosed in Phase 2..
06/2/202414:00GLOBEMiNK Therapeutics' AgenT-797 Shows Promising Results in the..
30/1/202414:00GLOBEMiNK’s AgenT-797 Offers New Hope in Overcoming ICI..
19/1/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:30GLOBEImmunoScape and MiNK Therapeutics Collaborate to Accelerate..
06/12/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202313:00EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMiNK Therapeutics Reports Third Quarter 2023 Results
03/11/202317:00GLOBEMiNK Therapeutics Presents Clinical Activity and Long-Term..
30/10/202313:00GLOBEMiNK to Provide Third Quarter 2023 Financial Report and..
17/10/202322:15EDGAR2Form 8-K - Current report
27/9/202315:05GLOBEMiNK Therapeutics To Present Data Update From Allogeneic..
06/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202314:30GLOBEMiNK Therapeutics to Participate in September Investor..
11/8/202313:44EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/8/202313:30EDGAR2Form 8-K - Current report
10/8/202313:30GLOBEMiNK Therapeutics Reports Second Quarter 2023 Results
10/8/202313:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/7/202314:30GLOBEMiNK to Provide Second Quarter 2023 Financial Report and..
05/6/202313:30GLOBEMiNK Therapeutics Announces Virtual Annual Shareholders..
22/5/202314:30GLOBEMiNK Presents Clinical Data on Allogeneic iNKT Cells..
18/5/202314:30GLOBEMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
11/5/202314:00GLOBEMiNK Therapeutics Reports Corporate Update and First Quarter..

Dernières Valeurs Consultées

NASDAQ
INKT
MiNK Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés